We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Refinitiv and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from our Featured Companies page.
Avacta
ESMO 2026 data supports pre|CISION PDC targetingAvacta
£12.5m raise completed, runway extended into Q227Scancell
Atlantic crossing transforms outlookAvacta
H126: pre|CISION pipeline progress prompts fundraiseAvacta
Encouraging first data from AVA6103 Phase Ia studyHUTCHMED
First ATTC deal: GSK $110m upfront for KRAS/EGFROxford BioDynamics
£9m raise gives management time to enact strategyHUTCHMED
SAFFRON data positions savo combo competitivelyHUTCHMED
H126: China recovery and Fruzaqla drive sales growthScancell
Strategic transactions to unlock longer-term value